PPARG has been shown to increase the chemosensitivity in several human carcinomas, including nonsmall-cell lung carcinoma, breast carcinoma, and pancreatic carcinoma [4–6]. This evidence concerns the gene PPARG and exocrine pancreatic carcinoma.